Edition:
Deutschland

Abbott Laboratories (ABT.N)

ABT.N on New York Stock Exchange

92.23USD
2 Jul 2020
Change (% chg)

$0.59 (+0.64%)
Prev Close
$91.64
Open
$92.38
Day's High
$93.05
Day's Low
$91.95
Volume
1,166,535
Avg. Vol
2,385,798
52-wk High
$99.99
52-wk Low
$61.62

About

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded... (more)

Buy/Sell

Sell Hold Buy
1.84 Mean rating from 19 analysts

Overall

Beta: 1.57
Market Cap(Mil.): $95,559.38
Shares Outstanding(Mil.): 1,737.44
Dividend: 0.26
Yield (%): 1.93

U.S. FDA allows emergency use of Danaher's COVID-19 antibody test

June 29 Medical device maker Danaher Corp said on Monday its COVID-19 blood test for detecting if a person had ever been infected with the new coronavirus received emergency use clearance from the U.S. Food and Drug Administration.

Many studies of COVID-19 antibody test accuracy fall short - review

ZURICH, June 25 Many studies assessing the accuracy of COVID-19 antibody tests had major shortcomings, a review released on Thursday concluded, offering further evidence the blood tests are of little use for people seeking to know with certainty if they have been infected.

Arizona's main COVID lab running behind as demand for tests soars to twice capacity

June 23 A spike in coronavirus infections in Arizona pushed demand for tests to twice the capacity of the state's main COVID lab last week, a senior laboratory executive said, adding that new testing equipment had been delayed two months.

BRIEF-FDA Says Request To Update Instructions For Use Of Abbott's Sars-CoV-2 IgG Assay Run On Architect I & Alinity I Systems Is Granted

* FDA IN LETTER DATED JUNE 22 SAYS REQUEST TO UPDATE INSTRUCTIONS FOR USE OF ABBOTT'S SARS-COV-2 IGG ASSAY RUN ON ARCHITECT I & ALINITY I SYSTEMS IS GRANTED Source text: (https://bit.ly/2YZLA7H) Further company coverage:

BRIEF-Abbott Laboratories Files For Potential 2-Part, Notes Offering

* ABBOTT LABORATORIES FILES FOR POTENTIAL 2-PART, NOTES OFFERING; SIZE NOT DISCLOSED - SEC FILING Source text: (https://bit.ly/3hT6Zrw) Further company coverage:

BRIEF-Abbott Laboratories Files For Potential Debt Shelf Offering

* ABBOTT LABORATORIES SAYS IT FILES FOR POTENTIAL DEBT SHELF OFFERING; SIZE NOT DISCLOSED - SEC FILING Source: (https://bit.ly/3i0wEim) Further company coverage:

Photo

U.S. health insurers may balk at paying for coronavirus antibody testing

NEW YORK U.S. health insurers may balk at covering tests that look for coronavirus antibodies in some cases, arguing that employers or the government should foot a bill expected to run into billions of dollars.

FOCUS-U.S. health insurers may balk at paying for coronavirus antibody testing

NEW YORK, June 16 U.S. health insurers may balk at covering tests that look for coronavirus antibodies in some cases, arguing that employers or the government should foot a bill expected to run into billions of dollars.

UPDATE 2-U.S. FDA clears new version of Abbott's low-cost glucose monitor

June 15 The U.S. Food and Drug Administration on Monday cleared a new version of Abbott Laboratories' continuous glucose monitoring device, helping the company build upon the success of its fastest-growing diabetes product.

Märkte

  • U.S.
  • Europa
  • Asien
  • Branchen

Branchenüberblick

Energie -0.12%
Rohstoffe +0.08%
Industrie -0.08%
Konjunktur abhängige Waren & Dienstleistungen -0.23%
Konjunktur unabhängige Waren & Dienstleistungen -0.10%
Finanzindustrie -0.03%
Pharma +0.06%
Technologie +0.22%
Telekommunikation -0.11%